Cytori Therapeutics (NASDAQ: CYTX) today announced that the Company’s Board of Directors has appointed Gary A. Lyons to serve as an independent director.

“Mr. Lyons will strengthen the broad expertise of our board and corporate governance given his successful track record in the biotechnology industry,” said Chris Calhoun, CEO of Cytori. “Specifically, he brings to Cytori a range of operational,
commercial, and corporate development experience at an important and exciting time in our Company’s development.”